Cytarabine

阿糖胞苷

Report date: 2022/12/07 17:06:47
NME

Base Information

Drug NameCytarabine
Drug Alias Name胞嘧啶阿拉伯糖苷cytarabinumArabinofuranosyl CytidineCytosine arabinosideCylocide +[16] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA-directed DNA polymerase inhibitorsDNA synthesis inhibitors
TargetsDNA-directed DNA polymerase
Therapy Area/IndicationsBrain metastasesCNS Embryonal TumorSolid tumours +[28] 
Global Approved IndicationsUrinary Bladder NeoplasmsUterine NeoplasmsLung Neoplasms +[14] 
Approved Indications in ChinaLeukemia, Biphenotypic, Acute
Original Approved Country/TerritoryUnited States
Original Approved Date1969/06/17
Country/TerritoryCanadaUnited StatesTaiwan +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTeva
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute NaplesNational Cancer InstituteChina Resources Saike Pharmaceutical Co Ltd +[6] 
Inactive CompaniesMundipharma Research LtdWake Forest University Health SciencesAntisoma Research Ltd +[16] 
Active IndicationsUrinary Bladder NeoplasmsUterine NeoplasmsLung Neoplasms +[12] 
Inactive IndicationsBrain metastasesCNS Embryonal TumorSolid tumours +[16] 

Other Information

ATC CodeL01BC01
Related LinksWikipediaDrugBankKEGG